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Abstract
Background: The development of genotyping and genetic sequencing techniques and their evolution towards low costs
and quick turnaround have encouraged a wide range of applications. One of the most promising applications is
pharmacogenomics, where genetic profiles are used to predict the most suitable drugs and drug dosages for the individual
patient. This approach aims to ensure appropriate medical treatment and avoid, or properly manage, undesired side effects.
Results: We developed the Medicine Safety Code (MSC) service, a novel pharmacogenomics decision support system, to
provide physicians and patients with the ability to represent pharmacogenomic data in computable form and to provide
pharmacogenomic guidance at the point-of-care. Pharmacogenomic data of individual patients are encoded as Quick
Response (QR) codes and can be decoded and interpreted with common mobile devices without requiring a centralized
repository for storing genetic patient data. In this paper, we present the first fully functional release of this system and
describe its architecture, which utilizes Web Ontology Language 2 (OWL 2) ontologies to formalize pharmacogenomic
knowledge and to provide clinical decision support functionalities.
Conclusions: The MSC system provides a novel approach for enabling the implementation of personalized medicine in
clinical routine.
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Introduction
The goal of personalized medicine is to better tailor healthcare
processes to the individual needs of patients. The use of genetic test
results and other individual molecular markers is one of the most
important means for achieving this goal [1]. While the range and
quantity of genomic information relevant to drug therapy is
growing rapidly, there are several challenges that need to be
addressed in order for clinicians to apply genomic information to
optimize therapy for their patients [2], such as:
& Processing complex genomic data generated by new sequenc-
ing technologies
& Identifying the effects of genomic variation on patient
outcomes
& Applying these findings in order to improve medical practice
Pharmacogenomics is the study of how variability in drug
response may correlate with the presence of certain sets of genetic
variants within an individual or across a population [3]. It
promotes the development of targeted therapies based on
individual genetic variants and is one of the most promising facets
of the personalized medicine research programme [4].
In recent years, pharmacogenomic studies have led to the
discovery of a large number of genetic variants that correspond to
drug response [5]. However, the limited pharmacogenomics
training of prescribing and consulting clinicians [6,7] and the
growth of genetic knowledge bases hinder the inclusion of
personalized medicine in clinical practice. The development of
clinical decision support (CDS) systems for genetically guided
personalized medicine has become an essential tool for anchoring
pharmacogenomics in clinical routine [8].
Several systems that implement pharmacogenomic CDS in local
institutions or regional infrastructures have been described. For
example, Swen et al. reported on procedures followed to
implement pharmacogenomic decision support rules in a nation-
wide computerized drug prescription system in the Netherlands
[9]. Pulley et al. reported encouraging results about using
pharmacogenomic CDS for anticoagulant therapy at the Vander-
bilt University Medical Center [10]. Lærum et al. recently reported
good feedback from clinicians when testing a prototype of a
pharmacogenomic decision support application for immunosup-
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pressant dosing [11]. Kawamoto et al. provide a comprehensive
review of clinical decision support systems for genome-based
personalized medicine [8].
The Medicine Safety Code (MSC) system we present here
provides a web-based, mobile-optimized CDS system aimed at
facilitating personalized medicine and clinical pharmacogenomics
across different institutions and regional infrastructures. Its goal is
to support physicians with customized drug dosage recommenda-
tions and other treatment recommendations based on the genetic
profiles of individual patients.
To achieve this goal, the MSC system needs to:
& Be able to parse genetic data to identify relevant genetic
variations.
& Formally represent knowledge of the pharmacogenomics
domain.
& Facilitate access to the inferred genetic markers and drug
dosage recommendations.
& Address security and privacy issues related to the processing of
personal health information.
& Be efficient enough to be deployed in routine medical care.
The current version of the MSC system is based on an early
prototype first presented in a prior manuscript [12]. This
prototype introduced the idea of encoding data on genetic
polymorphisms in a two-dimensional (2D) barcode and offering
a means to decode and interpret the data using common mobile
devices. In this paper, we present the technical aspects of the first
release of the full system, which is now based on ontological
reasoning.
We chose to base our system on formal ontologies, semantic
technologies and automated reasoning for implementing pharma-
cogenomic knowledge representation, quality assurance and
clinical decision support. The rationale for choosing this approach
was that in order to make effective use of pharmacogenomic
biomarkers in routine medical care and clinical trials, the
potentially large and complex data yielded by genotyping need
to be reduced to more manageable, higher-level characteristics
such as alleles, haplotypes, phenotypes or other classifications that
can help to predict drug response. These higher-level classifica-
tions need to be clearly defined in order to avoid errors and
inconsistencies in downstream clinical applications. This is a
source of potential ambiguity and complexity, making it difficult to
create reliable information technology systems for enabling clinical
pharmacogenomics. We found formal ontologies to be a very good
match to this problem domain.
In particular, we developed an OWL 2 ontology spanning from
basic genetic markers to inferred treatment recommendations
within a single, coherent model. This ontology contains a concise
logical formalization of clinical pharmacogenomic definitions and
rules. We use automated OWL 2 reasoning to detect potential
errors in our knowledge base as well as to implement the clinical
decision support algorithms for matching pharmacogenomic
guidelines to individual genetic profiles.
Materials and Methods
The MSC system provides two main functionalities: (1)
Processing a patient’s genotype profile to generate a two-
dimensional MSC Quick Response (QR) code. This makes it
possible for patients to carry their pharmacogenomic data with
them so that the data are available at the point-of-care whenever
needed. (2) Analyzing the genotype profile from a MSC QR code
and providing decision support messages based on a patient’s
genotype. This enables medical professionals to use pharmacoge-
nomic data contained in QR codes at the point-of-care.
The QR code specification [13] defines a standard 2D barcode
representation for the visual codification of arbitrary data. QR
codes have become very popular in media advertising campaigns
and retailing for several reasons:
& They can be easily printed on all kinds of media.
& They can be quickly and robustly decoded even under
suboptimal lighting conditions or viewing angles.
& Most current smartphones are shipped with pre-installed
applets for decoding QR codes.
& They allow for embedding web hyperlinks.
The data capacity of QR codes mainly depends on the sizes
(lines X columns) of the barcodes and their error correction levels.
According to the QR code specification, codes can represent up to
23,648 binary digits. This technology, therefore, is ideal for
systems that require a visual codification of data and a simple
methodology for passing information to a software application.
The MSC system uses QR code technology to represent the
genetic variants of a patient and to provide this information to
clinical decision support systems at the point-of-care in order to
obtain appropriate drug recommendations.
The workflow of the genetic profile processing functionality is
graphically described in Figure 1. A patient’s anonymous genetic
profile is uploaded to the web server and a suitable parser for the
file format is chosen. Then, the corresponding parser module
processes the genotype file and collects pharmacogenomic markers
relevant for generating the MSC.
The workflow of the second main functionality, the analysis of
the patient’s genetic profile, is presented in Figure 2. The MSC
server takes as input the resulting QR barcode from Figure 1, runs
a reasoner to infer matching CDS recommendations, and displays
the matching CDS recommendations as an interactive HTML
Figure 1. Processing a patient’s genetic profile and obtaining
the corresponding anonymous QR code.
doi:10.1371/journal.pone.0093769.g001
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page. The components of the system are described in more detail
below.
The MSC system is based on Java technologies and on the
model-view-controller software architecture. The user interface is
based on the JQuery Mobile framework [14] to facilitate access
from a wide variety of devices, including smart phones and tablets.
JQuery Mobile enables the development of touch-optimized
interfaces that automatically adapt to different screen sizes and
device capabilities. Figure 3 shows a graphical representation of
the module architecture.
OWL 2 ontology
We created a list of 58 genes and 385 polymorphisms relevant to
clinical pharmacogenomics by merging data from (a) the list of
‘very important pharmacogenes’ and their associated SNPs made
available by the Pharmacogenomics Knowledge Base
(PharmGKB) [15], (b) the PharmaADME core gene list [16],
and (c) markers mentioned in FDA drug labels [17], excluding
markers of somatic, non-inherited mutations. The following genes
were represented in the ontology: ABCB1, ABCC2, ABCG2,
ACE, ADRB1, ADRB2, AHR, ALOX5, BRCA1, COMT,
CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C19, CYP2C8,
CYP2C9, CYP2D6, CYP2J2, CYP3A4, CYP3A5, DPYD, DRD2,
F5, G6PD, GSTM1, GSTP1, HLA-B*1502, HLA-B*5701,
HMGCR, IL28B, KCNH2, KCNJ11, MTHFR, NAT1, NAT2,
NQO1, NR1I2, P2RY1, P2RY12, PTGIS, PTGS2, SCN5A,
SLC15A2, SLC19A1, SLC22A1, SLC22A2, SLC22A6,
SLCO1B1, SLCO1B3, SLCO2B1, SULT1A1, TPMT, TYMS,
UGT1A1, UGT2B15, UGT2B7 and VKORC1.
Top level classes and relations were created manually using the
Protege 4 ontology editing environment [18]. The remaining parts
of the ontology were developed via automated scripts as described
below. We used the dbSNP batch query interface to download the
dbSNP records for each of the 385 genetic markers.
We created scripts to parse PharmGKB haplotype/allele tables
and to create OWL axioms representing the definitions in these
tables. Since haplotypes are identified by sets of ‘‘tag’’ SNP
variants [19], we formalized these as ‘necessary and sufficient’
conditions expressed as equivalentClass axioms, while all other
known SNP variants were expressed as necessary conditions
through subClassOf axioms. A simple example of OWL axioms
created in this manner looks like this:
Class: ‘human with CYP2C9*3’
EquivalentTo:
has some rs1057910_C
SubClassOf:
has some ‘CYP2C9*3’,
(has some rs1057910_C) and
(has some rs1057911_A) and
(has some rs1799853_C) and
(has some rs2256871_A)
Decision support rules were created based on drug labels
approved by the U.S. Food and Drug Administration (FDA),
clinical guidelines of the clinical pharmacogenetics implementa-
tion consortium (CPIC) [20] and clinical guidelines of the Dutch
pharmacogenomics working group [21]. The following code
exemplifies an OWL representation of a dosing recommendation
for the drug warfarin as described in an FDA product label
(Coumadin, Bristol-Myers Squibb):
Class: ‘human triggering CDS rule 9’
Annotations:
CDS_message ‘‘0.5–2 mg warfarin per day
should be considered as a starting dose
range for a patient with this genotype
according to the warfarin drug label.’’
EquivalentTo:
(has some ‘CYP2C9*1’) and
(has some ‘CYP2C9*3’) and
Figure 2. Reading and interpreting a genotype profile from a
QR code.
doi:10.1371/journal.pone.0093769.g002
Figure 3. MSC system modules and their interactions.
doi:10.1371/journal.pone.0093769.g003
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(has exactly 2 rs9923231_T)
Clinical Decision Support in Pharmacogenetics module
The core of the MSC system is the Clinical Decision Support in
Pharmacogenetics module. This module implements the logic of the
MSC system that provides drug recommendations based on
patient genotype. The module accepts compressed data about the
patient’s genetic markers, decodes the data and infers the
corresponding recommendations using the Reasoning Engine mod-
ule. This module was implemented following the Singleton design
pattern [22]. The Singleton minimizes memory consumption
when offering common functions to several web requests and also
contains a pre-computed load instance of the empty model that is
used to reduce the processing time of each genotype analysis.
The Reasoning Engine module
The Reasoning Engine module was implemented using Semantic
Web technologies and based on the Genomic CDS ontology we
developed recently [23,24]. The Genomic CDS ontology is an
OWL 2 DL ontology containing pharmacogenomic domain
knowledge such as definitions of polymorphisms, alleles, pheno-
types and treatment recommendations. When the genetic profile
of a patient encoded in a QR barcode is submitted to the service,
an OWL representation of the genetic traits of the patient is
generated and combined with the domain knowledge in the
Genomic CDS ontology. Then, an OWL 2 reasoner is used to
infer matching alleles, phenotypes and treatment recommenda-
tions for the patient. We selected TrOWL 1.3 [25] as the main
reasoner for the MSC service because of its significant advantages
in reasoning performance and memory consumption compared to
other OWL 2 DL reasoners we tested with the Genomic CDS
ontology (paper under review).
The Genomic CDS ontology conceptualizes the pharmacoge-
nomics domain to represent the relations between humans, genetic
markers (based on allele variations) and drug dosage recommen-
dations. Figure 4 shows the excerpt of the Genomic CDS ontology
that represents how genotype information (‘‘Human with genotype
marker’’ and ‘‘Human with genetic polymorphism’’ classes) is linked to
patient (‘‘Human’’ class) and drug recommendations (‘‘Human
triggering CDS rule’’ class). The ontology currently contains
information on 1701 SNP variations, such as rs1142345_C which
represent the variation with nucleotide C in the SNP rs1142345 in
human chromosome 6. There are also 556 alleles defined as a
combination of SNP variations in the ontology, as well as 49 CDS
recommendations for 6 different medicines.
In this module, the OWL API [26] is utilized to manage
ontology access and reasoning capabilities provided by TrOWL.
Matching CDS recommendations are inferred in three steps: first,
the module is provided with the genetic profile of the patient;
second, the information is represented in a newly created copy of
the Genomic CDS ontology as an OWL individual of the class
‘‘human’’; third, the TrOWL reasoner computes the individual’s
inferred classes (i.e., it realises the OWL individual) and finally,
decision support messages attached to these inferred classes are
forwarded to the Clinical Decision Support in Pharmacogenetics module
to prepare the display of CDS recommendations.
The genetic profile code/decode module
The web server allows users to choose different types of
genotype file formats through the ‘‘Genetic Profile Encoder/
Decoder’’ module.
The current version of the MSC system supports two widely
used genetic file formats: the 23andMe format [27] and the
Variant Call Format (VCF) [28]. These file formats contain textual
representations of SNPs and the variants observed for each
individual patient. The module is implemented using the Factory
Method design pattern [22], which allows defining an interface to
create objects of different types but making it easier to extend the
system with new file parsers.
In the 23andMe file format, each line contains a pair of
nucleotides associated with a particular SNP identified with an ‘rs’
number from the dbSNP database. It also provides information
about the corresponding chromosome and position of the SNP.
Files generated by the currently available 23andMe direct-to-
consumer genetic test usually contain data about one million
SNPs.
VCF files contain three main sections: meta-information, a
header line and genotype information. The meta-information
section describes the keys and the elements used in the section of
genotype information. The header line indicates the order of tab-
delimited data fields. The last section represents genotype
information, with each line corresponding to a specific region in
the genome. In most VCF files, only deviations from a specific
human reference genome are listed, and missing information
about a specific SNP is assumed to imply that the patient’s genetic
sequence does not differ from the reference sequence. Therefore,
the MSC system assumes by default that the patient has the SNP
variants in the reference sequence if they are missing from the
VCF file.
QR code generation, decoding and interpretation
The QR code generator module compresses data about a patient’s
pharmacogenomic markers to generate a corresponding MSC QR
code. Internally, the genetic information of an individual is
represented as a long binary number. Bits at specific positions in
this binary number correspond to specific genetic polymorphisms
(such as specific SNPs) in the Genomic CDS ontology. After this
binary code has been generated from the patient’s pharmacogenomic
data, it is converted to a base 64 number to reduce its length and
facilitate its transmission through QR codes. The compressed and
encoded number is combined with the URL of MSC server (‘‘http://
safety-code.org/v0.2/,base_64_number.’’). An example of a URL
resulting from this process looks like this: http://safety-code.
org/v0.2/QXGqrLF2h8xuqzIyCGJE2hzPzVzrND_q0vtKk
Figure 4. Excerpt of the OWL 2 ontology used for inferring
matching polymorphisms and CDS rules from patient geno-
types.
doi:10.1371/journal.pone.0093769.g004
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2krxy0gQgDMlxWI0dzPwTq51w2UACs2nwZlF3QRxkv3uuu
Qtj4S55rDHGVU26maAZ203z-RCqhavsFv0a5uY1q770Su7_
dg80000
To decode and extract the genetic markers from an MSC, the
process described above is run in reverse: the base 64 number is
obtained from the URL and transformed into a binary number;
each combination of bits at specific positions in this binary number
corresponds to a particular genetic polymorphism in the Genomic
CDS ontology. The reasoning engine module creates an OWL
individual of the class ‘‘human’’, adds all genetic polymorphisms
decoded from the URL to this OWL individual and obtains CDS
recommendations that match the genetic profile of the patient.
Finally, the recommendations are displayed as an HTML page
and the MSC system releases the allocated resources, including the
populated instance of the Genomic CDS ontology, for the next
request.
Results and Discussion
The MSC service is publicly accessible at http://safety-code.
org/; the underlying source code and the most recent development
version of the ontology are available from http://code.google.
com/p/genomic-cds/ .
The MSC system makes it possible to encode and compress 385
genetic polymorphisms in a two-dimensional barcode and
provides the means to access the inferred drug recommendations
using common mobile devices. The system showcases complex
OWL 2 reasoning - based clinical decision support, has modest
system requirements, and allows implementation of future
extensions with little effort. Figure 5 demonstrates the interface
for uploading a genetic profile to generate an MSC QR code.
Some decision support algorithms can also be used through
manual entry of relevant genetic markers (Figure 6). The interface
for searching, browsing and displaying decision support messages
after decoding an MSC QR code is exemplified in Figure 7.
Figure 5. Interface to generate a QR code from a genetic profile in 23andMe or VCF format. For files in 23andMe format, the strand
orientation of the genetic information can be chosen.
doi:10.1371/journal.pone.0093769.g005
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Limitations and advantages
A major advantage of the MSC system is that it can provide an
open infrastructure for pharmacogenomic data sharing and
decision support with very limited dedicated infrastructure. Other
advantages are that sensitive genetic data are never explicitly
associated with patient identities in the system, that central storage
of genetic data is not necessary, and that local institutions can
potentially create their own infrastructures completely indepen-
dently.
The utilisation of an OWL 2 ontology to conceptualizes the
pharmacogenomic domain allows for sophisticated consistency
checking of the knowledge base, which helps to identify and
correct possible errors in the complex definitions and rules
encountered in pharmacogenomics. The Genomic CDS ontology
can be sustainably kept up-to-date with current knowledge
through semi-automated curation workflows based on data from
relevant data sources such as dbSNP and PharmGKB.
Another advantage of the MSC system is its mobile-friendly
interface, which automatically adapts to multiple mobile devices
such as smartphones or tablets. Consequently, it allows more
portability and flexibility than many established CDS systems, and
the functionality provided by the system can be exploited in most
health care settings. Mobile devices have been shown to help
improve medical decision making in realistic clinical settings [29].
A major barrier to the practical utilisation of the MSC system is
that pharmacogenomic testing is still not available to most
patients. We are currently building partnerships with genetic
testing providers to make genetic testing (and results in the form of
MSCs) more broadly available in routine care.
Another major barrier is user acceptance. The MSC system
aims to modify established workflows in the prescription and
utilisation of medications, which is bound to meet resistance from
both patients and medical practitioners.
According to an analysis of Kawamoto et al. [30] the success of
CDS interventions is significantly correlated with four features:
1) Automatic provision of decision support as part of clinician
workflow
2) Provision of recommendations rather than just assessments
3) Provision of decision support at the time and location of
decision making
4) Decision support is computer-based (rather than based on
non-electric systems)
While the MSC system exhibits features 2–4, we expect smooth
integration of the system into existing workflows to be the most
significant barrier towards user acceptance. The finding that
system-initiated decision support systems are more effective than
user-initiated systems is further substantiated by a study of Pearson
et al. [31].
In this context, it is noteworthy that 2D barcodes are likely to
become widely used for drug package tracking, tracing and
verification. In several countries and some states of the US 2D
barcodes on drug packages have recently become required by law
[32,33], and pharmacists and medical professionals are required to
scan medications before they are dispensed. The main motivation
behind these developments are improved logistics in the medica-
tion supply chain, substantially reduced incidence of errors in
medication dispensing [34], and the need to counter the growing
threat of counterfeit medications [35]. Albeit the majority of these
developments use GS1 DataMatrix barcodes [36] or other types of
barcodes instead of web-enabled QR codes, they will help establish
the use of 2D barcodes as a common practice in medication
handling and dispensing. This, in turn, might increase the chances
of a successful introduction of the MSC into existing clinical
workflows where quick scanning of 2D barcodes has become
routine practice. Scanning of medication barcodes and MSCs
Figure 6. Interface for manual entry of genetic traits.
doi:10.1371/journal.pone.0093769.g006
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could be integrated into a single app, which would also make it
easier to correlate medications with the pharmaceutical compound
that is about to be dispensed, as well as integrating drug-drug and
drug-drug-gene interaction alerts in the case of dispensation of
multiple medications.
Several studies on the effectiveness of CDS interventions in
improving physician prescribing behaviour have been published
over the last decade, but many studies also suffer from limited
sample size and poor reporting of system features that might be
associated with success [31,37]. Significant problems related to
system usability and information visualisation are commonly
reported, and the adaptation of systems based on user feedback
was demonstrated to improve user acceptance [38].
Both patients and medical practitioners might have doubts
about the trustworthiness, security and privacy implications of the
system. It is important that these issues are addressed with utmost
care and transparency. The integration of major stakeholders from
relevant areas of the health care space into development and
dissemination will be essential for gaining acceptance. This
includes clinicians, patient organisations, health insurance provid-
ers and pharmaceutical companies.
Previous work on guidelines for genome-guided therapy of
psychiatric drugs has led to the recognition of the importance of
considering pharmacogenomic information within the context of
other influences on drug effectiveness and safety, such as exposure
to potential drug-drug interactions, age-related clearance reduc-
tions, and co-morbidities [39]. Currently, the MSC is focused on
providing decision support based on genetic markers, leaving the
synthesis of pharmacogenomic findings with other patient
parameters to the medical professional. It can be argued that this
is a significant limitation of the system, and we plan to investigate
how the CDS algorithms currently employed by the system could
be enhanced to take other, non-genetic factors into account.
However, the integration of further parameters into decision
support algorithms might also make the validation of the system
very difficult. In this regard, the current, narrow focus on
matching patients to recommendations from existing clinical
guidelines that have been vetted by expert committees might also
be seen as a positive aspect of the system.
The amount of information that can be represented in a QR
code of practical dimensions is limited. Currently, the MSC system
captures data on 385 SNPs, but this number might be somewhat
increased by using more sophisticated compression algorithms, or
by encoding alleles and phenotypes instead of raw genetic markers
such as SNPs.
On the current server hardware (Intel Xeon E3-1230,
3,30 GHz, 16 GB RAM) and using TrOWL version 1.3, the
ontology-based reasoning engine takes 3 to 4 seconds to infer drug
recommendations. This response time is not optimal for use in
busy medical routine. The load on the OWL reasoner might
further grow when the size and complexity of future versions of the
Genomic CDS ontology increase. This issue is mitigated by the
fact that the MSC system includes a caching functionality, so that
results are available without delay for MSCs that have already
been decoded and cached once. Furthermore, the performance of
OWL reasoners – such as TrOWL – is still improving
continuously.
Related work
Several approaches towards representing pharmacogenomic
data through ontologies are described in the literature. We
analyzed these existing ontologies for their potential application to
Figure 7. Example of simple pharmacogenomics-based treatment recommendations generated from a QR code. The current user
interface displays basic recommendations, but future versions of the interface will also allow displaying further information – such as underlying
mechanisms and evidence – when required.
doi:10.1371/journal.pone.0093769.g007
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our use-case, but concluded that none of these existing resources
could be adapted to our needs. The SNP-Ontology and the Suggested
Ontology for Pharmacogenomics (SO-PHARM) [40] represent genetic
variation using OWL description logic. These ontologies were
formalized in OWL 1 and are unable to conveniently represent
relevant knowledge captured in the ontology we created, which
requires features that were introduced in OWL 2 (qualified
cardinality restrictions). The SNP-Ontology and SO-PHARM are
not actively maintained at the time of this writing. The Clinical
Bioinformatics Ontology (CBO) contains information about pharma-
cogenomic variants [41]. However, it does not contain logical
axioms for inferring alleles and matching guidelines through OWL
reasoning and is not actively maintained at the time of this writing.
GENO [42] is an ontological model of genotype information that
aims to support data integration across model organism databases.
GENO does not in itself represent important pharmacogenomic
variants, furthermore, it cannot be used for the kind of reasoning
and decision support enabled by the ontology we created.
There exists some previous work on CDS systems where
decision support logic is partly or fully based on OWL reasoning
and/or semantic technologies. One of the earliest examples is a
system developed by Bouamrane et al. [43], which employs OWL
reasoning together with other rule systems for preoperative
assessment in order to identify potential risks and complications.
A more recent example is the Lung Cancer Assistant system,
which employs OWL reasoning for lung cancer treatment
selection [44]. Douali et al. recently proposed a decision support
system enabling personalized treatment recommendations based
on Semantic Web tools and case-based fuzzy cognitive maps [45].
Alternative technologies that are competing with or are
complementary to the MSC system include:
1) Electronic health record (EHR) systems that are able to
capture pharmacogenomic data and provide decision support
at the point-of-care. Unfortunately, we expect that capable
EHR systems will remain unavailable or fragmented in most
regions in the foreseeable future.
2) Rapid genetic testing technologies that can be used at the
bedside and yield results in less than one hour. Currently, such
tests focus only on single genes and re-use of results is difficult.
We assume that the Medicine Safety Code system can still add
value in settings where such complementary technologies are
deployed, e.g., EHR systems might not be available to all
healthcare providers in a given region; the MSC decision support
module can be plugged into EHR systems; results from rapid
genetic tests can be captured as MSCs to save on assay costs in
future patient encounters.
Future work
We are currently working on updating the ontology used for
decision support, adding new genetic markers and a large number
of new decision support rules. We are also working on refining the
detection and representation of other polymorphisms besides
simple SNPs, such as insertions/deletions or short repeats. We will
also work on representing information about drug allergies in the
MSC.
Two important next steps need to be made towards practical
application are setting up a quality control and validation process
on one hand and conducting evaluations of the system in realistic
clinical settings on the other hand.
For the current version of the system, the correctness of inferred
recommendations was checked by ‘manually’ inspecting source
data and clinical guidelines, and comparing the inferences and
CDS messages made by the system with the source datasets and
guidelines. This kind of validation is not sufficient for proving the
system to be reliable enough for real clinical applications, and it is
also not very efficient, i.e., these validations would need to be
repeated with every new version of the system. We are therefore
creating a collection of several genetic profiles that will act as ‘test
cases’, and are setting up a system for automatically checking the
inferences generated for these test cases by our system, i.e., we are
working towards creating a more comprehensive unit testing
framework.
Since our long-term goal is to employ the system (or some of its
core components) for guiding medical decision making in clinical
settings, we will also work towards setting up a comprehensive
quality assurance system that is necessary for achieving certifica-
tion of the system as a medical device (which is a legal requirement
under EU and US legislation). The preparation for certification as
a medical device will include the creation of a detailed risk
analysis, setting up organisational workflows for responding to
problems, and strategies for keeping the system up-to-date in light
of new medical evidence.
The certification of the system as a medical device poses an
exquisite challenge. Quality control and the continuous integration
of new data into the system is facilitated by our reliance on (semi-
)automated scripts for data import, as well as the use of ontologies
and reasoners for knowledge base analysis and consistency
checking. Still, a significant ongoing effort is required for meeting
all criteria necessary for certification and maintaining a system that
is sufficiently reliable for clinical application – requirements that
are not easy to accommodate into classical academic research
environments. We are currently working on acquiring additional
funding for making sensitive modules of the system ready for
certification as a medical device. We are also investigating
monetization strategies to fund ongoing deployment and mainte-
nance of the system while establishing the Medicine Safety Code
as an open standard.
We are preparing for user tests with medical professionals and
pharmacists in order to optimize the system for use in realistic
clinical settings. Since the major focus of these first user
evaluations is on the overall usability and acceptance of the
system – and because the system will not be employed to guide
medical treatment – these user tests can run in parallel with efforts
for validating and certifying the decision support module.
Conclusions
The unique approach of the MSC system reduces some of the
patient confidentiality and technology acquisition barriers to the
storage, processing and communication of sensitive personal data.
The system could prove to be an enabling technology for the
emerging era of personalized medicine.
Availability and requirements
Project name: Medicine Safety Code web service
Project home page: https://code.google.com/p/genomic-
cds/
Operating system(s): Platform independent
Programming language: Java
License: Dual licensing: AGPL 3.0 (for open-source projects),
proprietary (for non-open-source projects)
Any restrictions to use by non-academics: Please contact
the corresponding author if you plan to use this software or
derivatives of this software for commercial purposes.
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